🚀 VC round data is live in beta, check it out!
Pharming Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pharming and similar public comparables like Keqian Biology, SanBio, Lepu Biopharma, Sana Biotechnology and more.
Pharming Overview
About Pharming
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Founded
1988
HQ
Employees
404
Website
Sectors
Financials (LTM)
EV
$1B
Pharming Financials
Pharming reported last 12-month revenue of $382M and EBITDA of $29M.
In the same LTM period, Pharming generated $340M in gross profit, $29M in EBITDA, and $7M in net income.
Revenue (LTM)
Pharming P&L
In the most recent fiscal year, Pharming reported revenue of $376M and EBITDA of $42M.
Pharming expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $382M | XXX | $376M | XXX | XXX | XXX |
| Gross Profit | $340M | XXX | $331M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $29M | XXX | $42M | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $7M | XXX | $3M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 1% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pharming Stock Performance
Pharming has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Pharming's stock price is $1.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -0.6% | XXX | XXX | XXX | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharming Valuation Multiples
Pharming trades at 2.8x EV/Revenue multiple, and 36.7x EV/EBITDA.
EV / Revenue (LTM)
Pharming Financial Valuation Multiples
As of March 21, 2026, Pharming has market cap of $1B and EV of $1B.
Equity research analysts estimate Pharming's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharming has a P/E ratio of 164.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 36.7x | XXX | 25.2x | XXX | XXX | XXX |
| EV/EBIT | 38.6x | XXX | 40.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | 3.2x | XXX | XXX | XXX |
| P/E | 164.9x | XXX | 385.5x | XXX | XXX | XXX |
| EV/FCF | (34.3x) | XXX | 19.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pharming Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pharming Margins & Growth Rates
Pharming's revenue in the last 12 month grew by 6%.
Pharming's revenue per employee in the last FY averaged $0.9M.
Pharming's rule of 40 is 14% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharming's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Pharming Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 57% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 35% | XXX | 21% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 27% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pharming Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| SanBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Lepu Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sana Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Chabiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharming M&A Activity
Pharming acquired XXX companies to date.
Last acquisition by Pharming was on XXXXXXXX, XXXXX. Pharming acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pharming
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharming Investment Activity
Pharming invested in XXX companies to date.
Pharming made its latest investment on XXXXXXXX, XXXXX. Pharming invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pharming
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pharming
| When was Pharming founded? | Pharming was founded in 1988. |
| Where is Pharming headquartered? | Pharming is headquartered in Netherlands. |
| How many employees does Pharming have? | As of today, Pharming has over 404 employees. |
| Who is the CEO of Pharming? | Pharming's CEO is Fabrice Chouraqui. |
| Is Pharming publicly listed? | Yes, Pharming is a public company listed on Euronext Amsterdam. |
| What is the stock symbol of Pharming? | Pharming trades under PHARM ticker. |
| When did Pharming go public? | Pharming went public in 1998. |
| Who are competitors of Pharming? | Pharming main competitors are Keqian Biology, SanBio, Lepu Biopharma, Sana Biotechnology. |
| What is the current market cap of Pharming? | Pharming's current market cap is $1B. |
| What is the current revenue of Pharming? | Pharming's last 12 months revenue is $382M. |
| What is the current revenue growth of Pharming? | Pharming revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Pharming? | Current revenue multiple of Pharming is 2.8x. |
| Is Pharming profitable? | Yes, Pharming is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharming? | Pharming's last 12 months EBITDA is $29M. |
| What is Pharming's EBITDA margin? | Pharming's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of Pharming? | Current EBITDA multiple of Pharming is 36.7x. |
| What is the current FCF of Pharming? | Pharming's last 12 months FCF is ($31M). |
| What is Pharming's FCF margin? | Pharming's last 12 months FCF margin is (8%). |
| What is the current EV/FCF multiple of Pharming? | Current FCF multiple of Pharming is (34.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.